Peer Reviewed Adjuvant Therapy Journals
Adjuvant therapy, also known as adjunct therapy, add-on therapy, and adjuvant care, is therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in
cancer therapy have led the term to be used mainly to describe adjuvant
cancer treatments. An example of such
adjuvant therapy is the additional treatment[1] usually given after
surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant. An adjuvant agent modifies the effect of another agent, so
adjuvant therapy modifies other therapy. The term "adjuvant therapy," derived from the Latin term adjuvÄre, meaning "to help," was first coined by Paul Carbone and his team at the National
Cancer Institute in 1963. In 1968, the National Surgical Adjuvant Breast and Bowel Project (NSABP) published its B-01 trial results for the first randomized trial that evaluated the effect of an adjuvant alkylating agent in breast cancer. The results indicated that the
adjuvant therapy given after the initial radical mastectomy "significantly decreased recurrence rate in pre-menopausal women with four or more positive axillary lymph nodes. The budding theory of using additional therapies to supplement primary
surgery was put into practice by Gianni Bonadonna and his colleagues from the Instituto Tumori in Italy in 1973, where they conducted a randomized trial that demonstrated more favorable survival outcomes that accompanied use of Cyclophosphamide Methotrexate Fluorouracil (CMF) after the initial mastectomy.